{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:50:23Z","timestamp":1769608223711,"version":"3.49.0"},"reference-count":133,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002531","name":"Kyungpook National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Oral Biosciences"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.job.2024.06.004","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T01:36:15Z","timestamp":1718933775000},"page":"496-503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Botulinum toxin type A is a potential therapeutic drug for chronic orofacial pain"],"prefix":"10.1016","volume":"66","author":[{"given":"Yu-Mi","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo-Young","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5570-2371","authenticated-orcid":false,"given":"Dong-Kuk","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.job.2024.06.004_bib1","first-page":"155","article-title":"The origin, structure, and pharmacological activity of botulinum toxin","volume":"33","author":"Simpson","year":"1981","journal-title":"Pharmacol Rev"},{"issue":"8","key":"10.1016\/j.job.2024.06.004_bib2","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1212\/WNL.53.8.1850","article-title":"Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the \"sausage poison\"","volume":"53","author":"Erbguth","year":"1999","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.job.2024.06.004_bib3","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1073\/pnas.96.6.3200","article-title":"Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals","volume":"96","author":"de Paiva","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6442","key":"10.1016\/j.job.2024.06.004_bib4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/365160a0","article-title":"Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25","volume":"365","author":"Blasi","year":"1993","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.job.2024.06.004_bib5","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/toxins16020076","article-title":"Botulinum toxin injections to the obliquus capitis inferioris muscle for dynamic cervical dystonia improves subjective patient outcomes","volume":"16","author":"Bessemer","year":"2024","journal-title":"Toxins"},{"issue":"4","key":"10.1016\/j.job.2024.06.004_bib6","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/WNL.37.4.616","article-title":"Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study","volume":"37","author":"Jankovic","year":"1987","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.job.2024.06.004_bib7","first-page":"212","article-title":"Treatment of spasticity with botulinum toxin","volume":"148","author":"M\u00e9min","year":"1992","journal-title":"Rev Neurol (Paris)"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3928\/0191-3913-19800101-06","article-title":"Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery","volume":"17","author":"Scott","year":"1980","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12886-022-02285-2","article-title":"Comparison of Botulinum toxin type A with surgery for the treatment of intermittent exotropia in children","volume":"22","author":"Su","year":"2022","journal-title":"BMC Ophthalmol"},{"issue":"5","key":"10.1016\/j.job.2024.06.004_bib10","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/0002-9394(88)90590-9","article-title":"Treatment of acquired nystagmus with botulinum A toxin","volume":"106","author":"Helveston","year":"1988","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.22599\/bioj.170","article-title":"The use of botulinum toxin in a case of acquired periodic alternating nystagmus","volume":"17","author":"Venturi","year":"2021","journal-title":"Br Ir Orthopt J"},{"issue":"11","key":"10.1016\/j.job.2024.06.004_bib12","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/j.1524-4725.1998.tb04092.x","article-title":"History of the cosmetic use of Botulinum A exotoxin","volume":"24","author":"Carruthers","year":"1998","journal-title":"Dermatol Surg"},{"issue":"4","key":"10.1016\/j.job.2024.06.004_bib13","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/jocd.16116","article-title":"Botulinium toxin applications in the lower face and neck: a comprehensive review","volume":"23","author":"Kassir","year":"2024","journal-title":"J Cosmet Dermatol"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib14","first-page":"59","article-title":"The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia","volume":"12","author":"Buchholz","year":"1997","journal-title":"Dysphagia"},{"issue":"2","key":"10.1016\/j.job.2024.06.004_bib15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/0883073815587030","article-title":"Comparison of efficacy and side effects of oral baclofen versus tizanidine therapy with adjuvant botulinum toxin type A in children with cerebral palsy and spastic equinus foot deformity","volume":"31","author":"Dai","year":"2016","journal-title":"J Child Neurol"},{"issue":"6","key":"10.1016\/j.job.2024.06.004_bib16","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2165\/00003495-199448060-00005","article-title":"Botulinum toxin in clinical practice","volume":"48","author":"Hughes","year":"1994","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.job.2024.06.004_bib17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/17474086.2017.1339598","article-title":"Side effects and potential risk factors of botulinum toxin type A intramuscular injections in knee flexion contractures of hemophiliacs","volume":"10","author":"Rodriguez-Merchan","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.job.2024.06.004_bib18","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3389\/fneur.2020.00716","article-title":"Botulinum neurotoxin for the treatment of neuropathic pain","volume":"11","author":"Egeo","year":"2020","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/toxins14010036","article-title":"A systematic review and Meta-Analysis of efficacy of botulinum toxin A for neuropathic pain","volume":"14","author":"Gupta","year":"2022","journal-title":"Toxins"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib20","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/s41598-023-49761-3","article-title":"A systematic review and network meta-analysis of pharmaceutical interventions used to manage chronic pain","volume":"14","author":"Shetty","year":"2024","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.job.2024.06.004_bib21","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.it.2017.12.003","article-title":"Immune cytokines and their receptors in inflammatory pain","volume":"39","author":"Cook","year":"2018","journal-title":"Trends Immunol"},{"key":"10.1016\/j.job.2024.06.004_bib22","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.3389\/fimmu.2019.03009","article-title":"Cytokines in pain: harnessing endogenous anti-inflammatory signaling for improved pain management","volume":"10","author":"Vanderwall","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/bja\/87.1.3","article-title":"Mechanisms of inflammatory pain","volume":"87","author":"Kidd","year":"2001","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.job.2024.06.004_bib24","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/783235","article-title":"Mediators of inflammation as targets for chronic pain treatment","volume":"2013","author":"Lipnik-Stangelj","year":"2013","journal-title":"Mediat Inflamm"},{"issue":"2\u20133","key":"10.1016\/j.job.2024.06.004_bib25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0014-2999(98)00508-1","article-title":"Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation","volume":"355","author":"Gilroy","year":"1998","journal-title":"Eur J Pharmacol"},{"issue":"32","key":"10.1016\/j.job.2024.06.004_bib26","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.2174\/092986709789578178","article-title":"Inhibitors of the microsomal prostaglandin E (2) synthase-1 as alternative to non-steroidal anti-inflammatory drugs (NSAIDs)-a critical review","volume":"16","author":"Koeberle","year":"2009","journal-title":"Curr Med Chem"},{"issue":"3","key":"10.1016\/j.job.2024.06.004_bib27","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0304-3959(99)00022-6","article-title":"Oral aspirin in postoperative pain: a quantitative systematic review","volume":"81","author":"Edwards","year":"1999","journal-title":"Pain"},{"issue":"5B","key":"10.1016\/j.job.2024.06.004_bib28","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/S0002-9343(99)00112-6","article-title":"Gastrointestinal effects of nonsteroidal anti-inflammatory therapy","volume":"106","author":"Raskin","year":"1999","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.job.2024.06.004_bib29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4196\/kjpp.2015.19.4.349","article-title":"Antinociceptive effects of transcytosed botulinum neurotoxin type A on trigeminal nociception in rats","volume":"19","author":"Kim","year":"2015","journal-title":"KOREAN J PHYSIOL PHARMACOL"},{"key":"10.1016\/j.job.2024.06.004_bib30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuroscience.2011.04.026","article-title":"Behavior and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A","volume":"186","author":"Matak","year":"2011","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00702-012-0846-3","article-title":"Comparison of analgesic effects of single versus repeated injection of botulinum toxin in orofacial formalin test in rats","volume":"120","author":"Matak","year":"2013","journal-title":"J Neural Transm"},{"issue":"8","key":"10.1016\/j.job.2024.06.004_bib32","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.pain.2014.04.027","article-title":"Botulinum toxin type A selectivity for certain types of pain is associated with capsaicin-sensitive neurons","volume":"155","author":"Matak","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.job.2024.06.004_bib33","article-title":"Analgesic potential of different available commercial brands of botulinum neurotoxin-A in formalin-induced orofacial pain in mice","volume":"12","author":"Cunha","year":"2021","journal-title":"Toxicon X"},{"issue":"1\u20132","key":"10.1016\/j.job.2024.06.004_bib34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pain.2003.10.008","article-title":"Subcutaneous administration of botulinum toxin A reduces formalin-induced pain","volume":"107","author":"Cui","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.job.2024.06.004_bib35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neuroscience.2017.06.004","article-title":"Antinociceptive effect of botulinum toxin A involves alterations in AMPA receptor expression and glutamate release in spinal dorsal horn neurons","volume":"357","author":"Hong","year":"2017","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib36","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.brainres.2006.01.117","article-title":"Botulinum neurotoxins and formalin-induced pain: central vs. peripheral effects in mice","volume":"1082","author":"Luvisetto","year":"2006","journal-title":"Brain Res"},{"key":"10.1016\/j.job.2024.06.004_bib37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neuroscience.2017.06.040","article-title":"Involvement of substance P in the antinociceptive effect of botulinum toxin type A: evidence from knockout mice","volume":"358","author":"Matak","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.job.2024.06.004_bib38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.toxicon.2014.12.007","article-title":"Analgesic effects of botulinum neurotoxin type A in a model of allylisothiocyanate- and capsaicin-induced pain in mice","volume":"94","author":"Luvisetto","year":"2015","journal-title":"Toxicon"},{"key":"10.1016\/j.job.2024.06.004_bib39","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejphar.2014.10.038","article-title":"Antinociceptive effect of botulinum toxin type A on experimental abdominal pain","volume":"745","author":"Drinovac","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"10.1016\/j.job.2024.06.004_bib40","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/WNR.0000000000000779","article-title":"Long-term anti-itch effect of botulinum neurotoxin A is associated with downregulation of TRPV1 and TRPA1 in the dorsal root ganglia in mice","volume":"28","author":"Cao","year":"2017","journal-title":"Neuroreport"},{"issue":"5","key":"10.1016\/j.job.2024.06.004_bib41","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1472-8206.2008.00615.x","article-title":"Lack of anti-inflammatory effect of botulinum toxin type A in experimental models of inflammation","volume":"22","author":"Bach-Rojecky","year":"2008","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.job.2024.06.004_bib42","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1155\/2014\/410415","article-title":"Blockade of glutamate release by botulinum neurotoxin type A in humans: a dermal microdialysis study","volume":"19","author":"Bittencourt da Silva","year":"2014","journal-title":"Pain Res Manag"},{"issue":"3","key":"10.1016\/j.job.2024.06.004_bib43","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.pain.2006.04.014","article-title":"The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization","volume":"122","author":"Gazerani","year":"2006","journal-title":"Pain"},{"issue":"1\u20132","key":"10.1016\/j.job.2024.06.004_bib44","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pain.2006.10.030","article-title":"Botulinum toxin type A reduces capsaicine-evoked pain and neurogenic vasodilatation in human skin","volume":"130","author":"Tugnoli","year":"2007","journal-title":"Pain"},{"issue":"1\u20132","key":"10.1016\/j.job.2024.06.004_bib45","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pain.2008.10.005","article-title":"Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin","volume":"141","author":"Gazerani","year":"2009","journal-title":"Pain"},{"issue":"12 suppl","key":"10.1016\/j.job.2024.06.004_bib46","doi-asserted-by":"crossref","first-page":"T33","DOI":"10.1016\/j.jpain.2013.07.018","article-title":"Clinical orofacial characteristics associated with risk of first-onset TMD: the OPPERA prospective cohort study","volume":"14","author":"Ohrbach","year":"2013","journal-title":"J Pain"},{"issue":"1\u20132","key":"10.1016\/j.job.2024.06.004_bib47","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.pain.2005.06.009","article-title":"Central cyclooxygenase inhibitors reduced IL-1\u03b2-induced hyperalgesia in temporomandibular joint of freely moving rats","volume":"117","author":"Ahn","year":"2005","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.job.2024.06.004_bib48","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3390\/toxins14030161","article-title":"Antinociceptive actions of botulinum toxin A1 on immunogenic hypersensitivity in temporomandibular joint of rats","volume":"14","author":"Mu\u00f1oz-Lora","year":"2022","journal-title":"Toxins"},{"key":"10.1016\/j.job.2024.06.004_bib49","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.toxicon.2017.02.010","article-title":"Botulinum toxin type A reduces inflammatory hypernociception induced by arthritis in the temporomadibular joint of rats","volume":"129","author":"Lora","year":"2017","journal-title":"Toxicon"},{"issue":"2","key":"10.1016\/j.job.2024.06.004_bib50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/bph.13366","article-title":"Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches","volume":"173","author":"Lackovi\u0107","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.job.2024.06.004_bib51","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.toxicon.2020.08.027","article-title":"Modulatory effect of botulinum toxin type A on the microglial P2X7\/CatS\/FKN activated-pathway in antigen-induced arthritis of the temporomandibular joint of rats","volume":"187","author":"Mu\u00f1oz-Lora","year":"2020","journal-title":"Toxicon"},{"issue":"6","key":"10.1016\/j.job.2024.06.004_bib52","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3390\/toxins12060395","article-title":"Efficacy and safety of botulinum toxin type A on persistent myofascial pain: a randomized clinical trial","volume":"12","author":"De la Torre Canales","year":"2020","journal-title":"Toxins"},{"issue":"2","key":"10.1016\/j.job.2024.06.004_bib53","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12663-014-0641-9","article-title":"Botulinum toxin in the treatment of muscle specific Oro-facial pain: a literature review","volume":"14","author":"Sunil Dutt","year":"2015","journal-title":"J Maxillofac Oral Surg"},{"key":"10.1016\/j.job.2024.06.004_bib54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.toxicon.2017.05.001","article-title":"Botulinum toxin type A reduces TRPV1 expression in the dorsal root ganglion in rats with adjuvant-arthritis pain","volume":"133","author":"Fan","year":"2017","journal-title":"Toxicon"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib55","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s12640-013-9447-7","article-title":"Anti-inflammatory effects of botulinum toxin type A in a complete freund's adjuvant-induced arthritic knee joint of hind leg on rat model","volume":"26","author":"Yoo","year":"2014","journal-title":"Neurotox Res"},{"key":"10.1016\/j.job.2024.06.004_bib56","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.toxicon.2019.12.153","article-title":"Botulinum toxin type A ameliorates adjuvant-arthritis pain by inhibiting microglial activation-mediated neuroinflammation and intracellular molecular signaling","volume":"178","author":"Shi","year":"2020","journal-title":"Toxicon"},{"issue":"10","key":"10.1016\/j.job.2024.06.004_bib57","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrrheum.2014.64","article-title":"Mechanisms, impact and management of pain in rheumatoid arthritis","volume":"10","author":"Walsh","year":"2014","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.job.2024.06.004_bib58","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1055\/s-0036-1594284","article-title":"Botulinum toxin injections in musculoskeletal disorders","volume":"20","author":"Godoy","year":"2016","journal-title":"Semin Muscoskel Radiol"},{"issue":"9","key":"10.1016\/j.job.2024.06.004_bib59","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision","volume":"17","author":"Attal","year":"2010","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.neuron.2006.09.021","article-title":"Mechanisms of neuropathic pain","volume":"52","author":"Campbell","year":"2006","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.job.2024.06.004_bib61","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2007.08.033","article-title":"Pharmacologic management of neuropathic pain: evidence-based recommendations","volume":"132","author":"Dworkin","year":"2007","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib62","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/PL00005748","article-title":"Characterization of heat-hyperalgesia in an experimental trigeminal neuropathy in rats","volume":"116","author":"Imamura","year":"1997","journal-title":"Exp Brain Res"},{"issue":"6","key":"10.1016\/j.job.2024.06.004_bib63","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.pnpbp.2007.05.016","article-title":"Intracisternal administration of mitogen-activated protein kinase inhibitors reduced mechanical allodynia following chronic constriction injury of infraorbital nerve in rats","volume":"31","author":"Lim","year":"2007","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"Suppl 3","key":"10.1016\/j.job.2024.06.004_bib64","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1017\/S0317167100000135","article-title":"Neural mechanisms and pathways in craniofacial pain","author":"Sessle","year":"1999","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.job.2024.06.004_bib65","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.neulet.2016.11.043","article-title":"Botulinum neurotoxin type A alleviates mechanical hypersensitivity associated with infraorbital nerve constriction injury in rats","volume":"637","author":"Noma","year":"2017","journal-title":"Neurosci Lett"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib66","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2842.2011.02236.x","article-title":"Intradermal injection of Botulinum toxin type A alleviates infraorbital nerve constriction-induced thermal hyperalgesia in an operant assay","volume":"39","author":"Kumada","year":"2012","journal-title":"J Oral Rehabil"},{"key":"10.1016\/j.job.2024.06.004_bib67","first-page":"431","article-title":"Central antinociceptive activity of peripherally applied botulinum toxin type A in lab rat model of trigeminal neuralgia","volume":"5","author":"Wu","year":"2016","journal-title":"Spring"},{"issue":"10","key":"10.1016\/j.job.2024.06.004_bib68","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/WNR.0000000000001268","article-title":"Botulinum toxin type A reduces the expression of transient receptor potential melastatin 3 and transient receptor potential vanilloid type 4 in the trigeminal subnucleus caudalis of a rat model of trigeminal neuralgia","volume":"30","author":"Zhang","year":"2019","journal-title":"Neuroreport"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib69","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s10194-021-01254-2","article-title":"Unilateral facial injection of Botulinum neurotoxin A attenuates bilateral trigeminal neuropathic pain and anxiety-like behaviors through inhibition of TLR2-mediated neuroinflammation in mice","volume":"22","author":"Chen","year":"2021","journal-title":"J Headache Pain"},{"issue":"4","key":"10.1016\/j.job.2024.06.004_bib70","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1526-4637.2010.00801.x","article-title":"Use of botulinum toxin type A injection for neuropathic pain after trigeminal nerve injury","volume":"11","author":"Yoon","year":"2010","journal-title":"Pain Med"},{"issue":"9","key":"10.1016\/j.job.2024.06.004_bib71","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/0022034510374056","article-title":"Early dexamethasone relieves trigeminal neuropathic pain","volume":"89","author":"Han","year":"2010","journal-title":"J Dent Res"},{"issue":"10","key":"10.1016\/j.job.2024.06.004_bib72","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1177\/0022034516659278","article-title":"Antinociceptive effects of Botulinum Toxin Type A on trigeminal neuropathic pain","volume":"95","author":"Yang","year":"2016","journal-title":"J Dent Res"},{"issue":"2","key":"10.1016\/j.job.2024.06.004_bib73","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00702-004-0265-1","article-title":"Botulinum toxin type A in experimental neuropathic pain","volume":"112","author":"Bach-Rojecky","year":"2005","journal-title":"J Neural Transm"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib74","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.neuroscience.2010.08.067","article-title":"Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models","volume":"171","author":"Marinelli","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.job.2024.06.004_bib75","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bbi.2013.01.088","article-title":"Botulinum toxin A increases analgesic effects of morphine, counters development of morphine tolerance and modulates glia activation and \u03bc opioid receptor expression in neuropathic mice","volume":"32","author":"Vacca","year":"2013","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.job.2024.06.004_bib76","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ejphar.2016.09.019","article-title":"Participation of pro- and anti-nociceptive interleukins in botulinum toxin A-induced analgesia in a rat model of neuropathic pain","volume":"791","author":"Zychowska","year":"2016","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib77","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13578-020-00501-4","article-title":"Botulinum toxin type A alleviates neuropathic pain and suppresses inflammatory cytokines release from microglia by targeting TLR2\/MyD88 and SNAP23","volume":"10","author":"Wang","year":"2020","journal-title":"Cell Biosci"},{"issue":"4","key":"10.1016\/j.job.2024.06.004_bib78","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3344\/kjp.2022.35.4.391","article-title":"The role of botulinum toxin type A related axon transport in neuropathic pain induced by chronic constriction injury","volume":"35","author":"Bu","year":"2022","journal-title":"Korean J Pain"},{"key":"10.1016\/j.job.2024.06.004_bib79","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.neuroscience.2019.10.007","article-title":"SNAP-25 contributes to neuropathic pain by regulation of VGLuT2 expression in rats","volume":"423","author":"Wang","year":"2019","journal-title":"Neuroscience"},{"issue":"1\u20133","key":"10.1016\/j.job.2024.06.004_bib80","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejphar.2009.06.047","article-title":"Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models","volume":"617","author":"Favre-Guilmard","year":"2009","journal-title":"Eur J Pharmacol"},{"issue":"1\u20133","key":"10.1016\/j.job.2024.06.004_bib81","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejphar.2010.01.020","article-title":"Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection","volume":"633","author":"Bach-Rojecky","year":"2010","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.job.2024.06.004_bib82","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/BF03022619","article-title":"The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain","volume":"53","author":"Park","year":"2006","journal-title":"Can J Anaesth"},{"key":"10.1016\/j.job.2024.06.004_bib83","series-title":"Pain and central nervous system disease","first-page":"13","article-title":"Introduction: semantic, epidemiologic, and educational issues in: casey KL","author":"Bonica","year":"1991"},{"issue":"4","key":"10.1016\/j.job.2024.06.004_bib84","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/ana.24605","article-title":"Botulinum toxin type A for neuropathic pain in patients with spinal cord injury","volume":"79","author":"Han","year":"2016","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.job.2024.06.004_bib85","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1682\/JRRD.2005.02.0033","article-title":"Prevalence and characteristics of chronic pain in veterans with spinal cord injury","volume":"42","author":"Rintala","year":"2005","journal-title":"J Rehabil Res Dev"},{"issue":"1\u20132","key":"10.1016\/j.job.2024.06.004_bib86","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3959(99)00023-8","article-title":"Pain report and the relationship of pain to physical factors in the first 6 months following spinal cord injury","volume":"81","author":"Siddall","year":"1999","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.job.2024.06.004_bib87","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0304-3959(02)00452-9","article-title":"A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury","volume":"103","author":"Siddall","year":"2003","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.job.2024.06.004_bib88","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/apmr.2001.21855","article-title":"Chronic pain associated with spinal cord injury: a community survey","volume":"82","author":"Turner","year":"2001","journal-title":"Arch Phys Med Rehabil"},{"issue":"2","key":"10.1016\/j.job.2024.06.004_bib89","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00002508-199206000-00005","article-title":"Chronic pain and spinal cord injury","volume":"8","author":"Mariano","year":"1992","journal-title":"Clin J Pain"},{"issue":"2","key":"10.1016\/j.job.2024.06.004_bib90","first-page":"46","article-title":"Deafferentation pain after spinal cord injury. Part I. theoretical aspects","volume":"9","author":"Segatore","year":"1992","journal-title":"Sci Nurs"},{"issue":"2\u20133","key":"10.1016\/j.job.2024.06.004_bib91","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0304-3959(96)03178-8","article-title":"Pain following spinal cord injury: the clinical problem and experimental studies","volume":"68","author":"Yezierski","year":"1996","journal-title":"Pain"},{"key":"10.1016\/j.job.2024.06.004_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.602417","article-title":"Combination of botulinum toxin and minocycline ameliorates neuropathic pain through antioxidant stress and anti-inflammation via promoting SIRT1 pathway","volume":"11","author":"Yu","year":"2021","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.job.2024.06.004_bib93","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1526-4637.2011.01182.x","article-title":"Botulinum toxin decreases hyperalgesia and inhibits P2X3 receptor over-expression in sensory neurons induced by ventral root transection in rats","volume":"12","author":"Xiao","year":"2011","journal-title":"Pain Med"},{"issue":"2","key":"10.1016\/j.job.2024.06.004_bib94","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/pme.12017","article-title":"Botulinum toxin type A reduces hyperalgesia and TRPV1 expression in rats with neuropathic pain","volume":"14","author":"Xiao","year":"2013","journal-title":"Pain Med"},{"issue":"6","key":"10.1016\/j.job.2024.06.004_bib95","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.sc.3102022","article-title":"Impact of spinal cord injury on self-perceived pre- and postmorbid cognitive, emotional and physical functioning","volume":"45","author":"Murray","year":"2007","journal-title":"Spinal Cord"},{"issue":"11","key":"10.1016\/j.job.2024.06.004_bib96","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0003-9993(98)90240-4","article-title":"Quality of life and traumatic spinal cord injury","volume":"79","author":"Westgren","year":"1998","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.job.2024.06.004_bib97","doi-asserted-by":"crossref","DOI":"10.1177\/1744806920901890","article-title":"Trigeminal neuralgia: an overview from pathophysiology to pharmacological treatments","volume":"16","author":"Gambeta","year":"2020","journal-title":"Mol Pain"},{"issue":"4","key":"10.1016\/j.job.2024.06.004_bib98","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41415-024-7068-6","article-title":"Trigeminal neuralgia and trigeminal neuropathic pain","volume":"236","author":"Ryan","year":"2024","journal-title":"Br Dent J"},{"issue":"4","key":"10.1016\/j.job.2024.06.004_bib99","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.wnf.0000172497.24770.b0","article-title":"Botulinum toxin and intractable trigeminal neuralgia","volume":"28","author":"T\u00fcrk","year":"2005","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"10.1016\/j.job.2024.06.004_bib100","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3171\/jns.1980.52.3.0381","article-title":"Microvascular relations of the trigeminal nerve. An anatomical study with clinical correlation","volume":"52","author":"Haines","year":"1980","journal-title":"J Neurosurg"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib101","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3171\/jns.1967.26.1part2.0159","article-title":"Arterial compression of the trigeminal nerve at the pons in patients with trigeminal neuralgia","volume":"26","author":"Jannetta","year":"1967","journal-title":"J Neurosurg"},{"issue":"1\u20132","key":"10.1016\/j.job.2024.06.004_bib102","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0304-3959(99)00310-3","article-title":"Trigeminal neuralgia: opportunities for research and treatment","volume":"85","author":"Kitt","year":"2000","journal-title":"Pain"},{"issue":"2","key":"10.1016\/j.job.2024.06.004_bib103","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pnpbp.2012.03.002","article-title":"A novel trigeminal neuropathic pain model: compression of the trigeminal nerve root produces prolonged nociception in rats","volume":"38","author":"Jeon","year":"2012","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.job.2024.06.004_bib104","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0030-4220(92)90292-X","article-title":"Drugs used in the management of trigeminal neuralgia","volume":"74","author":"Zakrzewska","year":"1992","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1016\/j.job.2024.06.004_bib105","series-title":"Trigeminal neuralgia. A Practical approach to management","first-page":"80","article-title":"Medical management","volume":"28","author":"Patsalos","year":"1995"},{"key":"10.1016\/j.job.2024.06.004_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.neuro.051508.135531","article-title":"Neuropathic pain: a maladaptive response of the nervous system to damage","volume":"32","author":"Costigan","year":"2009","journal-title":"Annu Rev Neurosci"},{"issue":"6","key":"10.1016\/j.job.2024.06.004_bib107","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/0333102412441721","article-title":"Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial","volume":"32","author":"Wu","year":"2012","journal-title":"Cephalalgia"},{"key":"10.1016\/j.job.2024.06.004_bib108","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.2147\/JPR.S168650","article-title":"Botulinum toxin-A for the treatment of neuralgia: a systematic review and meta-analysis","volume":"11","author":"Meng","year":"2018","journal-title":"J Pain Res"},{"issue":"10","key":"10.1016\/j.job.2024.06.004_bib109","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1409","article-title":"The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: a meta-analysis of randomized controlled trials","volume":"9","author":"Wei","year":"2019","journal-title":"Brain Behav"},{"issue":"12","key":"10.1016\/j.job.2024.06.004_bib110","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.jpain.2022.08.004","article-title":"Cellular mechanisms mediating the antinociceptive effect of botulinum toxin A in a rodent model of trigeminal irritation by a foreign body","volume":"23","author":"Cho","year":"2022","journal-title":"J Pain"},{"issue":"10","key":"10.1016\/j.job.2024.06.004_bib111","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1007\/s11064-023-03969-x","article-title":"Intrathecal injection of botulinum toxin type A has an analgesic effect in male rats CCI model by inhibiting the activation of spinal P2X4R","volume":"48","author":"Zhou","year":"2023","journal-title":"Neurochem Res"},{"key":"10.1016\/j.job.2024.06.004_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.npep.2023.102346","article-title":"Intrathecal administration of botulinum toxin type a antagonizes neuropathic pain by countering increased vesicular nucleotide transporter expression in the spinal cord of chronic constriction injury of the sciatic nerve rats","volume":"100","author":"Shi","year":"2023","journal-title":"Neuropeptides"},{"key":"10.1016\/j.job.2024.06.004_bib113","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neuint.2018.03.010","article-title":"Botulinum toxin type A and gabapentin attenuate postoperative pain and NK1 receptor internalization in rats","volume":"116","author":"Li","year":"2018","journal-title":"Neurochem Int"},{"issue":"2","key":"10.1016\/j.job.2024.06.004_bib114","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/toxins10020066","article-title":"The effect of botulinum neurotoxin serotype a heavy chain on the growth related proteins and neurite outgrowth after spinal cord injury in rats","volume":"10","author":"Wang","year":"2018","journal-title":"Toxins"},{"issue":"10","key":"10.1016\/j.job.2024.06.004_bib115","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/ejp.513","article-title":"Intrathecal administration of botulinum toxin type A improves urinary bladder function and reduces pain in rats with cystitis","volume":"18","author":"Coelho","year":"2014","journal-title":"Eur J Pain"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib116","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1213\/ANE.0b013e3181ffa1d7","article-title":"Intrathecal administration of botulinum neurotoxin type A attenuates formalin-induced nociceptive responses in mice","volume":"112","author":"Lee","year":"2011","journal-title":"Anesth Analg"},{"issue":"8","key":"10.1016\/j.job.2024.06.004_bib117","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/pm\/pnaa028","article-title":"CGRP plasma levels decrease in classical trigeminal neuralgia patients treated with botulinum toxin type A: a pilot study","volume":"21","author":"Zhang","year":"2020","journal-title":"Pain Med"},{"issue":"9","key":"10.1016\/j.job.2024.06.004_bib118","doi-asserted-by":"crossref","DOI":"10.1177\/03000605211047704","article-title":"Botulinum toxin A for management of refractory concurrent buccal and inferior alveolar nerve post-traumatic neuropathies: a case report","volume":"50","author":"Capon","year":"2022","journal-title":"J Int Med Res"},{"issue":"Suppl 1","key":"10.1016\/j.job.2024.06.004_bib119","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/sc.2014.43","article-title":"Effect of subcutaneous injection of botulinum toxin A on spinal cord injury-associated neuropathic pain","volume":"52","author":"Han","year":"2014","journal-title":"Spinal Cord"},{"issue":"Pt A","key":"10.1016\/j.job.2024.06.004_bib120","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.toxicon.2015.08.001","article-title":"Clinical differences between botulinum neurotoxin type A and B","volume":"107","author":"Bentivoglio","year":"2015","journal-title":"Toxicon"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib121","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1111\/ejn.13261","article-title":"Effects of intraplantar botulinum toxin-B on carrageenan-induced changes in nociception and spinal phosphorylation of GluA1 and Akt","volume":"44","author":"Sikandar","year":"2016","journal-title":"Eur J Neurosci"},{"issue":"4","key":"10.1016\/j.job.2024.06.004_bib122","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.pain.2013.12.009","article-title":"Botulinum toxin B in the sensory afferent: transmitter release, spinal activation, and pain behavior","volume":"155","author":"Marino","year":"2014","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.job.2024.06.004_bib123","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019126","article-title":"Spinal Botulinum Neurotoxin B: effects on afferent transmitter release and nociceptive processing","volume":"6","author":"Huang","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.job.2024.06.004_bib124","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/toxins10030128","article-title":"Botulinum toxin B affects neuropathic pain but not functional recovery after peripheral nerve injury in a mouse model","volume":"10","author":"Finocchiaro","year":"2018","journal-title":"Toxins"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib125","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1213\/ANE.0000000000000777","article-title":"The effects of intraplantar and intrathecal botulinum toxin type B on tactile allodynia in mono and polyneuropathy in the mouse","volume":"121","author":"Park","year":"2015","journal-title":"Anesth Analg"},{"issue":"4","key":"10.1016\/j.job.2024.06.004_bib126","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1083\/jcb.200406126","article-title":"Botulinum neurotoxin C initiates two different programs for neurite degeneration and neuronal apoptosis","volume":"168","author":"Berliocchi","year":"2005","journal-title":"J Cell Biol"},{"issue":"5","key":"10.1016\/j.job.2024.06.004_bib127","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/(SICI)1097-4547(19980601)52:5<569::AID-JNR9>3.0.CO;2-A","article-title":"Syntaxin and 25-kDa synaptosomal-associated protein: differential effects of botulinum neurotoxins C1 and A on neuronal survival","volume":"52","author":"Williamson","year":"1998","journal-title":"J Neurosci Res"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib128","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/WNR.0b013e328330dcca","article-title":"Type C botulinum toxin causes degeneration of motoneurons in vivo","volume":"21","author":"Zhao","year":"2010","journal-title":"Neuroreport"},{"issue":"8","key":"10.1016\/j.job.2024.06.004_bib129","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrmicro3295","article-title":"Botulinum neurotoxins genetic, structural and mechanistric insights","volume":"12","author":"Rossetto","year":"2014","journal-title":"Nat Rev Microbiol"},{"issue":"6","key":"10.1016\/j.job.2024.06.004_bib130","doi-asserted-by":"crossref","first-page":"847e","DOI":"10.1097\/PRS.0000000000005029","article-title":"Safety and efficacy of EB-001, a novel type E botulinum toxin, in subjects with glabellar frown lines: results of a phase 2, randomized, placebo-controlled, ascending-dose study","volume":"142","author":"Yoelin","year":"2018","journal-title":"Plast Reconstr Surg"},{"issue":"12","key":"10.1016\/j.job.2024.06.004_bib131","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3390\/toxins13120834","article-title":"New modified recombinant botulinum neurotoxin type F with enhanced potency","volume":"13","author":"Burgin","year":"2021","journal-title":"Toxins"},{"key":"10.1016\/j.job.2024.06.004_bib132","series-title":"Botulinum toxin","article-title":"Botulinum toxins, diversity, mode of action, epidemiology of botulism in France","author":"Popoff","year":"2018"},{"issue":"1","key":"10.1016\/j.job.2024.06.004_bib133","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1128\/mr.56.1.80-99.1992","article-title":"Properties and use of botulinum toxin and other microbial neurotoxins in medicine","volume":"56","author":"Schantz","year":"1992","journal-title":"Microbiol Rev"}],"container-title":["Journal of Oral Biosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1349007924001415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1349007924001415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T02:47:10Z","timestamp":1723603630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1349007924001415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":133,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1349007924001415"],"URL":"https:\/\/doi.org\/10.1016\/j.job.2024.06.004","relation":{},"ISSN":["1349-0079"],"issn-type":[{"value":"1349-0079","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Botulinum toxin type A is a potential therapeutic drug for chronic orofacial pain","name":"articletitle","label":"Article Title"},{"value":"Journal of Oral Biosciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.job.2024.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Association for Oral Biology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}